Cargando…
Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
Skeletal muscle depletion is common in patients with advanced cancer and may be associated with a poor outcome. To investigate whether the changes in skeletal muscle in metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy are associated with clinical outcome, we undertook an ob...
Autores principales: | Gu, Weijie, Wu, Junlong, Liu, Xiaohang, Zhang, Hailiang, Shi, Guohai, Zhu, Yao, Ye, Dingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548774/ https://www.ncbi.nlm.nih.gov/pubmed/28790354 http://dx.doi.org/10.1038/s41598-017-07955-6 |
Ejemplares similares
-
Prognostic Value of Components of Body Composition in Patients Treated with Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Case Series
por: Gu, Weijie, et al.
Publicado: (2015) -
Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma
por: Wang, Beihe, et al.
Publicado: (2019) -
Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma
por: Wu, Junlong, et al.
Publicado: (2019) -
Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma
por: Gu, Weijie, et al.
Publicado: (2015) -
Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib
por: Lu, Xiaolin, et al.
Publicado: (2016)